SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed A Complaint To Recover Losses Suffered By Purchasers Of Cytokinetics, Incorporated Common Stock And Sets A Lead Plaintiff Deadline Of November 17, 2025

(MENAFN- GlobeNewsWire - Nasdaq) NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired common stock of Cytokinetics, Incorporated (“Cytokinetics” or the“Company”) (NASDAQ: CYTK) between December 27, 2023, to May 6, 2025, inclusive. You are hereby notified that the class action lawsuit Judah Seidman v. Cytokinetics, Incorporated, et al. (Case No. 3:25-cv-07923) has been commenced in the United States District Court for the Northern District of California. To get more information go to:

or contact Joseph E. Levi, Esq. either via email at ... or by telephone at (212) 363-7500. There is no cost or obligation to you.

According to the complaint, defendants made materially false and misleading statements regarding the timeline for the New Drug Application (“NDA”) submission and approval process for aficamten. Specifically, defendants represented that the Company expected approval from the U.S. Food and Drug Administration (“FDA”) for its NDA for aficamten in the second half of 2025, based on a September 26, 2025 PDUFA date, and failed to disclose material risks related to the Company's failure to submit a Risk Evaluation and Mitigation Strategy (“REMS”) that could delay the regulatory process.

On May 6, 2025, during an earnings call, it was revealed that the Company had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. This confirmed defendants' awareness of potential REMS requirements and their reckless decision to omit it from the initial submission, misleading investors about the regulatory timeline.

As a result of defendants' false and misleading statements, class members purchased Cytokinetics' common stock at artificially inflated prices and suffered significant losses when the truth was revealed.

If you suffered a loss in CYTK common stock, you have until November 17, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
...
Tel: (212) 363-7500
Fax: (212) 363-7171

MENAFN17092025004107003653ID1110076633